MedBioSphere
Articles Videos The Web  
    

Roberts Pharmaceutical Corporation

Selected Abstract

Roberts Pharmaceutical Corporation Announces Priority Review Status in Canada For Its New Drug Agrylin And Plans to File This Year For European Approval
EATONTOWN, , , N.J., March 6 /PRNewswire/ -- Rob er Pharmaceutical Corporation (Nasdaq: RPCX) announced today that its new drug AGRYLIN(TM) has been given Priority Review status by the Health Protection Branch, Canada (HPB). Roberts filed a New Drug Submission for AGRYLIN with the Canadian ...
March 6, 1997; PR Newswire

Read the full article with a free-trial membership at HighBeam Research



Related Articles

1. Roberts Pharmaceutical Corporation Receives License from Wyeth Laboratories To Market Lodine in the U.K. and Ireland
2. Roberts Pharmaceutical Corporation Announces Agreement in Principle to Settle Class Action Lawsuit - Continued Profitability Expected -
3. Roberts Pharmaceutical Corporation Concludes Special Shareholders Meeting and Also Notes FDA Labeling Review of Agrelin in Progress
4. Roberts Pharmaceutical Corporation Announces Sale of VRG International, A Contract Research Business; Expects First-Quarter Earnings to Exceed Estimates
5. Roberts Pharmaceutical Corporation Announces the Sale of Two Product Lines to Monarch Pharmaceuticals
6. Roberts Pharmaceutical Corporation Updates Third Quarter Outlook
7. Roberts Pharmaceutical Corporation Receives Patent to Year 2017 for New Process to Manufacture its Drug Agrylin
8. Roberts Pharmaceutical Corporation and Eli Lilly and Company to Expand Agreement for Compounds in Development for Large Gastrointestinal Market
9. Roberts Pharmaceutical Corporation Receives Canadian Approval For Its New Drug Agrylin
10. Roberts Pharmaceutical Corporation Concludes $115 Million Equity Placements